WO2010074540A2 - 음이온성 약물 함유 약제학적 조성물 및 그 제조방법 - Google Patents

음이온성 약물 함유 약제학적 조성물 및 그 제조방법 Download PDF

Info

Publication number
WO2010074540A2
WO2010074540A2 PCT/KR2009/007804 KR2009007804W WO2010074540A2 WO 2010074540 A2 WO2010074540 A2 WO 2010074540A2 KR 2009007804 W KR2009007804 W KR 2009007804W WO 2010074540 A2 WO2010074540 A2 WO 2010074540A2
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
anionic drug
production method
anionic
composition containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/007804
Other languages
English (en)
French (fr)
Other versions
WO2010074540A3 (ko
Inventor
김세호
손지연
나문호
최성원
서민효
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Samyang Corp
Original Assignee
Samyang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP09835306.3A priority Critical patent/EP2377517B1/en
Priority to US13/141,101 priority patent/US20110268772A1/en
Priority to NZ594245A priority patent/NZ594245A/xx
Priority to CN200980156062.9A priority patent/CN102300556B/zh
Priority to CA2748520A priority patent/CA2748520C/en
Priority to JP2011543435A priority patent/JP5592897B2/ja
Application filed by Samyang Corp filed Critical Samyang Corp
Priority to AU2009330859A priority patent/AU2009330859B2/en
Publication of WO2010074540A2 publication Critical patent/WO2010074540A2/ko
Publication of WO2010074540A3 publication Critical patent/WO2010074540A3/ko
Anticipated expiration legal-status Critical
Priority to US15/137,167 priority patent/US10292932B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

유효성분으로서 음이온성 약물; 양이온성 지질; 및 양친성 블록 공중합체를 포함하며, 상기 음이온성 약물은 상기 양이온성 지질과 복합체를 형성하고, 상기 복합체가 양친성 블록 공중합체의 미셀 구조 내부에 봉입되어 있는 것을 특징으로 하는 음이온성 약물 함유 약제학적 조성물과 그 제조방법이 개시된다. 상기 약제학적 조성물은, 음이온성 약물의 혈중 혹은 체액 내 안정성을 높일 수 있으며, 세포내 전달을 가능케 하여 음이온성 약물의 효능을 향상시킬 수 있다는 장점이 있다.
PCT/KR2009/007804 2008-12-26 2009-12-24 음이온성 약물 함유 약제학적 조성물 및 그 제조방법 Ceased WO2010074540A2 (ko)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US13/141,101 US20110268772A1 (en) 2008-12-26 2009-12-24 Pharmaceutical composition containing an anionic drug and a production method thereof
NZ594245A NZ594245A (en) 2008-12-26 2009-12-24 Pharmaceutical composition containing an anionic drug, a cationic lipid and an amphiphilic block copolymer
CN200980156062.9A CN102300556B (zh) 2008-12-26 2009-12-24 含有阴离子药物的药物组合物及其制备方法
CA2748520A CA2748520C (en) 2008-12-26 2009-12-24 Pharmaceutical composition containing an anionic drug, and a production method therefor
JP2011543435A JP5592897B2 (ja) 2008-12-26 2009-12-24 アニオン性薬物含有薬剤学的組成物及びその製造方法
EP09835306.3A EP2377517B1 (en) 2008-12-26 2009-12-24 Pharmaceutical composition containing an anionic drug, and a production method therefor
AU2009330859A AU2009330859B2 (en) 2008-12-26 2009-12-24 Pharmaceutical composition containing an anionic drug, and a production method therefor
US15/137,167 US10292932B2 (en) 2008-12-26 2016-04-25 Polymeric micelle particle comprising anionic drugs and method of preparing the same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20080134459 2008-12-26
KR10-2008-0134459 2008-12-26
KR1020090130794A KR101209265B1 (ko) 2008-12-26 2009-12-24 음이온성 약물 함유 약제학적 조성물 및 그 제조방법
KR10-2009-0130794 2009-12-24

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/141,101 A-371-Of-International US20110268772A1 (en) 2008-12-26 2009-12-24 Pharmaceutical composition containing an anionic drug and a production method thereof
US15/137,167 Continuation-In-Part US10292932B2 (en) 2008-12-26 2016-04-25 Polymeric micelle particle comprising anionic drugs and method of preparing the same

Publications (2)

Publication Number Publication Date
WO2010074540A2 true WO2010074540A2 (ko) 2010-07-01
WO2010074540A3 WO2010074540A3 (ko) 2010-11-11

Family

ID=42638507

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/007804 Ceased WO2010074540A2 (ko) 2008-12-26 2009-12-24 음이온성 약물 함유 약제학적 조성물 및 그 제조방법

Country Status (9)

Country Link
US (1) US20110268772A1 (ko)
EP (1) EP2377517B1 (ko)
JP (1) JP5592897B2 (ko)
KR (1) KR101209265B1 (ko)
CN (1) CN102300556B (ko)
AU (1) AU2009330859B2 (ko)
CA (1) CA2748520C (ko)
NZ (1) NZ594245A (ko)
WO (1) WO2010074540A2 (ko)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120107377A1 (en) * 2009-08-31 2012-05-03 Yasuki Kato Particulate composition and pharmaceutical composition containing the same
KR101495298B1 (ko) * 2013-02-20 2015-02-25 한국과학기술원 소간섭 리보핵산(siRNA)를 친수성 블록으로 갖는 양친매성 블록 공중합체 및 이를 포함하는 다중이온복합체
EP2801615A4 (en) * 2012-01-05 2015-08-19 Bioneer Corp HIGHLY EFFICIENT NANOPARTICULAR DOUBLE HELIX OLIGO RNA STRUCTURE AND METHOD FOR THE PRODUCTION THEREOF
AU2011215177B2 (en) * 2010-02-12 2015-10-15 Nanocarrier Co., Ltd. Particulate medicinal composition
US9439856B2 (en) 2012-04-04 2016-09-13 Samyang Biopharmaceuticals Corporation Method of preparing composition for delivering an anionic drug
EP3695850A1 (en) * 2010-12-30 2020-08-19 Samyang Biopharmaceuticals Corporation Carrier for negatively charged drugs comprising a cationic lipid and a preparation method thereof

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102109188B1 (ko) 2013-04-01 2020-05-11 삼성전자주식회사 양이온성 지질을 포함하는 온도민감성 리포좀 및 그의 용도
US10710044B2 (en) * 2015-04-02 2020-07-14 Nanyang Technological University Tubular and vesicular architectures formed from polymer-lipid blends and method for forming the same
MX386005B (es) * 2015-09-15 2025-03-18 Samyang Holdings Corp Composicion farmaceutica que contiene farmaco anionico, y metodo de preparacion para la misma.
CN105396121A (zh) * 2015-11-20 2016-03-16 钟志容 Gx1修饰的阴离子脂质体腺病毒载体及其制备方法与应用
CN105362251B (zh) * 2015-12-14 2019-02-26 四川大学 DOTAP-mPEG-PLA纳米粒及其纳米粒溶液、载药复合物和制备方法和应用
DK3391875T3 (da) * 2015-12-18 2022-01-24 Samyang Holdings Corp Fremgangsmåde til fremstilling af polymer micelle, der indeholder et anionisk lægemiddel
CN105860057B (zh) * 2016-05-10 2018-01-19 苏州大学 基于疏水功能性小分子‑亲水聚氨基酸的生物可降解聚合物及其制备方法和应用
KR101949507B1 (ko) * 2016-11-09 2019-02-18 주식회사 삼양바이오팜 Kras를 표적으로 하는 핵산 함유 약제학적 조성물 및 그 제조방법
US11179466B2 (en) 2016-12-14 2021-11-23 Samyang Holdings Corporation Amphiphilic block copolymer composition having enhanced micelle stability, and pharmaceutical composition comprising same
KR101916941B1 (ko) * 2016-12-30 2018-11-08 주식회사 삼양바이오팜 플라스미드 디엔에이 전달용 고분자 나노입자 조성물 및 그의 제조방법
WO2019013255A1 (ja) * 2017-07-11 2019-01-17 学校法人東京薬科大学 核酸送達用組成物及び核酸含有組成物
CN109276541B (zh) * 2017-07-19 2021-05-14 浙江圣兆药物科技股份有限公司 一种可调节药物释放的脂质体组合物及其制备方法
KR102175069B1 (ko) * 2017-11-10 2020-11-05 주식회사 삼양바이오팜 음이온성 약물 전달용 지질 나노입자의 동결건조 조성물 및 방법
AU2020379482B2 (en) * 2019-11-07 2026-05-07 Samyang Holdings Corporation Polymer nanoparticle composition for inducing immunity and preparation method therefor
CN114181200B (zh) * 2021-11-24 2023-09-29 华中科技大学 一种具有高效基因转染效率的阳离子脂质体及制备与应用
CN117122698A (zh) * 2023-03-24 2023-11-28 上海谊众药业股份有限公司 一种特异性结合神经紧张素特异性受体（ntr）的靶向多肽修饰的纳米载药递送系统（pdc）的制备方法与应用
CN117427174B (zh) * 2023-12-20 2024-05-31 百达联康生物科技(深圳)有限公司 一种用于核酸药物的复合材料及其制备方法和应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0180334B1 (ko) 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
US20020086356A1 (en) 2000-03-30 2002-07-04 Whitehead Institute For Biomedical Research RNA sequence-specific mediators of RNA interference
US6458382B1 (en) 1999-11-12 2002-10-01 Mirus Corporation Nucleic acid transfer complexes
US20030073640A1 (en) 1997-07-23 2003-04-17 Ribozyme Pharmaceuticals, Inc. Novel compositions for the delivery of negatively charged molecules
WO2005007196A2 (en) 2003-07-16 2005-01-27 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
US7056704B2 (en) 2000-12-01 2006-06-06 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. RNA interference mediating small RNA molecules
WO2009078685A2 (en) 2007-12-18 2009-06-25 Dong Ki Lee Novel sirna structure for minimizing off-target effects and relaxing saturation of rnai machinery and the use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040295A (en) * 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
JP2001510457A (ja) * 1996-11-12 2001-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インビボ送達に有効な、脂質―核酸複合体の安定な製剤の調製
WO2002100435A1 (en) * 2001-06-11 2002-12-19 Centre Hospitalier Universitaire De Montreal Compositions and methods for enhancing nucleic acid transfer into cells
EP1441763A2 (en) * 2001-11-07 2004-08-04 Inex Pharmaceuticals Corp. Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
AU2003288902A1 (en) * 2002-09-06 2004-04-08 Genteric, Inc. Microcapsules and methods of use
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
JP2007512355A (ja) * 2003-11-21 2007-05-17 アルザ コーポレイション 開裂性のｐｅｇで表面修飾されたリポソーム−ｄｎａ複合体で媒介される遺伝子送達
CA2564616C (en) * 2004-04-20 2016-08-30 Nastech Pharmaceutical Company Inc. Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells
CA2564719C (en) 2004-05-06 2011-11-01 Samyang Corporation Delivery system for bioactive agents on the basis of a polymeric drug carrier comprising an amphiphilic block polymer and a polylactic acid derivative
CN101646462A (zh) * 2007-03-30 2010-02-10 大塚制药株式会社 药物转运控制用经肺给药脂质体
CA2723192A1 (en) * 2008-05-07 2009-11-12 Surmodics, Inc. Delivery of nucleic acid complexes from particles
WO2010026537A1 (en) * 2008-09-05 2010-03-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Novel multimodular assembly useful for intracellular delivery

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0180334B1 (ko) 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
US20030073640A1 (en) 1997-07-23 2003-04-17 Ribozyme Pharmaceuticals, Inc. Novel compositions for the delivery of negatively charged molecules
US6458382B1 (en) 1999-11-12 2002-10-01 Mirus Corporation Nucleic acid transfer complexes
US20020086356A1 (en) 2000-03-30 2002-07-04 Whitehead Institute For Biomedical Research RNA sequence-specific mediators of RNA interference
US7056704B2 (en) 2000-12-01 2006-06-06 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. RNA interference mediating small RNA molecules
WO2005007196A2 (en) 2003-07-16 2005-01-27 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
US20060240093A1 (en) 2003-07-16 2006-10-26 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
WO2009078685A2 (en) 2007-12-18 2009-06-25 Dong Ki Lee Novel sirna structure for minimizing off-target effects and relaxing saturation of rnai machinery and the use thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BLIGH, EG., DYER, WJ: "A rapid method of total lipid extraction and purification", CAN. J. BIOCHEM. PHYSIOL, vol. 37, 1959, pages 911 - 937
DE PAULA D, BENTLEY MV, MAHATO RI: "Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting", RNA, vol. 13, 2007, pages 431 - 56
ELBASHIR ET AL., GENES DEV., vol. 15, 2001, pages 188
GARY DJ, PURI N, WON YY: "Polymer-based siRNA delivery: Perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery", J CONTROL RELEASE, vol. 121, 2007, pages 64 - 73, XP022179907, DOI: doi:10.1016/j.jconrel.2007.05.021
MCMANUS, SHARP, NATURE REV. GENET., vol. 3, 2002, pages 737
See also references of EP2377517A4

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120107377A1 (en) * 2009-08-31 2012-05-03 Yasuki Kato Particulate composition and pharmaceutical composition containing the same
AU2010287391B2 (en) * 2009-08-31 2016-02-25 Nanocarrier Co., Ltd. Particle composition and medicinal composition comprising same
US9415059B2 (en) * 2009-08-31 2016-08-16 Nanocarrier Co., Ltd. Particulate composition and pharmaceutical composition containing the same
AU2011215177B2 (en) * 2010-02-12 2015-10-15 Nanocarrier Co., Ltd. Particulate medicinal composition
EP3695850A1 (en) * 2010-12-30 2020-08-19 Samyang Biopharmaceuticals Corporation Carrier for negatively charged drugs comprising a cationic lipid and a preparation method thereof
EP2801615A4 (en) * 2012-01-05 2015-08-19 Bioneer Corp HIGHLY EFFICIENT NANOPARTICULAR DOUBLE HELIX OLIGO RNA STRUCTURE AND METHOD FOR THE PRODUCTION THEREOF
US9439856B2 (en) 2012-04-04 2016-09-13 Samyang Biopharmaceuticals Corporation Method of preparing composition for delivering an anionic drug
KR101495298B1 (ko) * 2013-02-20 2015-02-25 한국과학기술원 소간섭 리보핵산(siRNA)를 친수성 블록으로 갖는 양친매성 블록 공중합체 및 이를 포함하는 다중이온복합체

Also Published As

Publication number Publication date
CN102300556B (zh) 2015-04-29
KR101209265B1 (ko) 2012-12-06
US20110268772A1 (en) 2011-11-03
EP2377517A4 (en) 2013-12-25
KR20100076905A (ko) 2010-07-06
EP2377517B1 (en) 2020-01-22
JP5592897B2 (ja) 2014-09-17
WO2010074540A3 (ko) 2010-11-11
NZ594245A (en) 2013-02-22
AU2009330859B2 (en) 2013-06-20
JP2012513460A (ja) 2012-06-14
CN102300556A (zh) 2011-12-28
CA2748520C (en) 2013-12-17
CA2748520A1 (en) 2010-07-01
EP2377517A2 (en) 2011-10-19
AU2009330859A1 (en) 2011-08-18

Similar Documents

Publication Publication Date Title
WO2010074540A3 (ko) 음이온성 약물 함유 약제학적 조성물 및 그 제조방법
WO2012091523A3 (en) Carrier for negatively charged drugs comprising a cationic lipid and a preparation method thereof
WO2005112886A3 (en) Methods and articles for the delivery of therapeutic agents
WO2008103409A3 (en) Compositions of chloroquine coupled to antibodies and to other proteins with methods for their synthesis
WO2007103557A3 (en) Coating capsules with active pharmaceutical ingredients
WO2008058547A3 (en) Alpha-lactalbumin composition
WO2008060964A3 (en) Unit dosage package and methods for administering weight loss medications
WO2008144340A3 (en) Drug delivery system with scleral lens
WO2011143201A3 (en) Ratiometric combinatorial drug delivery
WO2009109927A3 (en) Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
HK1211867A1 (en) Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
BR112012003283A2 (pt) sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente.
WO2006039704A3 (en) Pharmaceutical composition and method for treating a joint capsule arthropathy
WO2012021107A3 (en) A liposomal formulation for ocular drug delivery
WO2010021607A3 (en) Pharmaceutical formulation
WO2007109684A3 (en) Dose packaging system for load-dose titration administration of a liquid formulation
MY157187A (en) Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2010092450A8 (en) Stable pharmaceutical composition for atherosclerosis
WO2006029845A3 (en) Delivery vehicle containing nanoparticles
WO2008109385A3 (en) Oral administration of a calcitonin
WO2010098627A3 (ko) 약제학적 제제
IL179012A (en) A drug containing cetirizine for the treatment of nasal inflammation, a process for its preparation and use
AU2013330679A8 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
WO2008038126A3 (en) Packaging system for pharmaceutical compositions and kit for intravenous administration
WO2008051527A3 (en) Sustained release of agents for localized pain management

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980156062.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09835306

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 13141101

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2009835306

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011543435

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2748520

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 5338/DELNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009330859

Country of ref document: AU

Ref document number: 594245

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2009330859

Country of ref document: AU

Date of ref document: 20091224

Kind code of ref document: A